Literature DB >> 33407005

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission.

Young-Il Kim1,2, Se-Mi Kim1,2, Su-Jin Park1,2,3, Eun-Ha Kim1,2, Kwang-Min Yu1,2, Jae-Hyung Chang1, Eun Ji Kim1, Mark Anthony B Casel1,2, Rare Rollon1, Seung-Gyu Jang1, Jihye Um4, Min-Suk Song1,2, Hye Won Jeong1, Eung-Gook Kim1, Yeonjae Kim4, So Yeon Kim4, Jun-Sun Park4, Mi Sun Park5, Geun-Yong Kwon6, Sang Gu Yeo5, Shin-Ae Lee7, Youn Jung Choi7, Jae U Jung7, Young Ki Choi1,2.   

Abstract

Cases of laboratory-confirmed SARS-CoV-2 reinfection have been reported in a number of countries. Further, the level of natural immunity induced by SARS-CoV-2 infection is not fully clear, nor is it clear if a primary infection is protective against reinfection. To investigate the potential association between serum antibody titres and reinfection of SARS-CoV-2, ferrets with different levels of NAb titres after primary SARS-CoV-2 infection were subjected to reinfection with a heterologous SARS-CoV-2 strain. All heterologous SARS-CoV-2 reinfected ferrets showed active virus replication in the upper respiratory and gastro-intestinal tracts. However, the high NAb titre group showed attenuated viral replication and rapid viral clearance. In addition, direct-contact transmission was observed only from reinfected ferrets with low NAb titres (<20), and not from other groups. Further, lung histopathology demonstrated the presence of limited inflammatory regions in the high NAb titre groups compared with control and low NAb groups. This study demonstrates a close correlation between a low NAb titre and SARS-CoV-2 reinfection in a recovered ferret reinfection model.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; ferret model; neutralizing antibody; reinfection

Mesh:

Substances:

Year:  2021        PMID: 33407005      PMCID: PMC7832474          DOI: 10.1080/22221751.2021.1872352

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


  20 in total

1.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

Authors:  Quan-Xin Long; Xiao-Jun Tang; Qiu-Lin Shi; Qin Li; Hai-Jun Deng; Jun Yuan; Jie-Li Hu; Wei Xu; Yong Zhang; Fa-Jin Lv; Kun Su; Fan Zhang; Jiang Gong; Bo Wu; Xia-Mao Liu; Jin-Jing Li; Jing-Fu Qiu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-06-18       Impact factor: 53.440

2.  Disappearance of antibodies to SARS-associated coronavirus after recovery.

Authors:  Wu-Chun Cao; Wei Liu; Pan-He Zhang; Fang Zhang; Jan H Richardus
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

3.  Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages.

Authors:  C W Olsen; W V Corapi; C K Ngichabe; J D Baines; F W Scott
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

4.  Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee.

Authors:  Manish M Patel; Natalie J Thornburg; William B Stubblefield; H Keipp Talbot; Melissa M Coughlin; Leora R Feldstein; Wesley H Self
Journal:  JAMA       Date:  2020-11-03       Impact factor: 56.272

5.  Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody.

Authors:  Katherine V Houser; Andrew J Broadbent; Lisa Gretebeck; Leatrice Vogel; Elaine W Lamirande; Troy Sutton; Kevin W Bock; Mahnaz Minai; Marlene Orandle; Ian N Moore; Kanta Subbarao
Journal:  PLoS Pathog       Date:  2017-08-17       Impact factor: 6.823

6.  Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.

Authors:  F Javier Ibarrondo; Jennifer A Fulcher; David Goodman-Meza; Julie Elliott; Christian Hofmann; Mary A Hausner; Kathie G Ferbas; Nicole H Tobin; Grace M Aldrovandi; Otto O Yang
Journal:  N Engl J Med       Date:  2020-07-21       Impact factor: 91.245

7.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

Authors:  Abishek Chandrashekar; Jinyan Liu; Amanda J Martinot; Katherine McMahan; Noe B Mercado; Lauren Peter; Lisa H Tostanoski; Jingyou Yu; Zoltan Maliga; Michael Nekorchuk; Kathleen Busman-Sahay; Margaret Terry; Linda M Wrijil; Sarah Ducat; David R Martinez; Caroline Atyeo; Stephanie Fischinger; John S Burke; Matthew D Slein; Laurent Pessaint; Alex Van Ry; Jack Greenhouse; Tammy Taylor; Kelvin Blade; Anthony Cook; Brad Finneyfrock; Renita Brown; Elyse Teow; Jason Velasco; Roland Zahn; Frank Wegmann; Peter Abbink; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Xuan He; Catherine Jacob-Dolan; Nicole Kordana; Zhenfeng Li; Michelle A Lifton; Shant H Mahrokhian; Lori F Maxfield; Ramya Nityanandam; Joseph P Nkolola; Aaron G Schmidt; Andrew D Miller; Ralph S Baric; Galit Alter; Peter K Sorger; Jacob D Estes; Hanne Andersen; Mark G Lewis; Dan H Barouch
Journal:  Science       Date:  2020-05-20       Impact factor: 47.728

8.  Duration of antibody responses after severe acute respiratory syndrome.

Authors:  Li-Ping Wu; Nai-Chang Wang; Yi-Hua Chang; Xiang-Yi Tian; Dan-Yu Na; Li-Yuan Zhang; Lei Zheng; Tao Lan; Lin-Fa Wang; Guo-Dong Liang
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

9.  Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya.

Authors:  Patience K Kiyuka; Charles N Agoti; Patrick K Munywoki; Regina Njeru; Anne Bett; James R Otieno; Grieven P Otieno; Everlyn Kamau; Taane G Clark; Lia van der Hoek; Paul Kellam; D James Nokes; Matthew Cotten
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

10.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

View more
  21 in total

1.  Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients.

Authors:  Michael Paal; Florian M Arend; Tobias Lau; Sandra Hasmann; Daniela Soreth-Rieke; Johanna Sorodoc-Otto; Wilke Beuthien; Julia Krappe; Marcell Toepfer; Gero von Gersdorff; Norbert Thaller; Simon Rau; Bernd Northoff; Daniel Teupser; Mathias Bruegel; Michael Fischereder; Ulf Schönermarck
Journal:  Clin Kidney J       Date:  2021-07-06

2.  Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.

Authors:  Yang Yang; Minghui Yang; Yun Peng; Yanhua Liang; Jing Yuan; Yingxia Liu; Jinli Wei; Li Xing; Liping Guo; Xiaohe Li; Jie Li; Jun Wang; Mianhuan Li; Zhixiang Xu; Mingxia Zhang; Fuxiang Wang; Yi Shi
Journal:  Nat Microbiol       Date:  2022-02-07       Impact factor: 30.964

Review 3.  Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals.

Authors:  David A Meekins; Natasha N Gaudreault; Juergen A Richt
Journal:  Viruses       Date:  2021-10-04       Impact factor: 5.048

4.  Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.

Authors:  Josiane Warszawski; Anne-Lise Beaumont; Rémonie Seng; Xavier de Lamballerie; Delphine Rahib; Nathalie Lydié; Rémy Slama; Sylvain Durrleman; Philippe Raynaud; Patrick Sillard; François Beck; Laurence Meyer; Nathalie Bajos
Journal:  BMC Infect Dis       Date:  2022-01-09       Impact factor: 3.090

5.  Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.

Authors:  Edwards Pradenas; Benjamin Trinité; Víctor Urrea; Silvia Marfil; Ferran Tarrés-Freixas; Raquel Ortiz; Carla Rovirosa; Jordi Rodon; Júlia Vergara-Alert; Joaquim Segalés; Victor Guallar; Alfonso Valencia; Nuria Izquierdo-Useros; Marc Noguera-Julian; Jorge Carrillo; Roger Paredes; Lourdes Mateu; Anna Chamorro; Ruth Toledo; Marta Massanella; Bonaventura Clotet; Julià Blanco
Journal:  Cell Rep Med       Date:  2022-01-24

6.  Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.

Authors:  Qiu-Yan Xu; Jian-Hang Xue; Yao Xiao; Zhi-Juan Jia; Meng-Juan Wu; Yan-Yun Liu; Wei-Li Li; Xian-Ming Liang; Tian-Ci Yang
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

7.  Latex Microsphere-Based Bicolor Immunochromatography for Qualitative Detection of Neutralizing Antibody against SARS-CoV-2.

Authors:  Zhanwei Liang; Tao Peng; Xueshima Jiao; Yang Zhao; Jie Xie; You Jiang; Bo Meng; Xiang Fang; Xiaoping Yu; Xinhua Dai
Journal:  Biosensors (Basel)       Date:  2022-02-07

8.  A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era.

Authors:  Sean C Taylor
Journal:  J Clin Virol Plus       Date:  2021-10-08

Review 9.  Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.

Authors:  Natalie Yan-Lin Pang; Alexander Shao-Rong Pang; Vincent T Chow; De-Yun Wang
Journal:  Mil Med Res       Date:  2021-08-31

10.  B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination.

Authors:  Prasanti Kotagiri; Federica Mescia; William M Rae; Laura Bergamaschi; Zewen K Tuong; Lorinda Turner; Kelvin Hunter; Pehuén P Gerber; Myra Hosmillo; Christoph Hess; Menna R Clatworthy; Ian G Goodfellow; Nicholas J Matheson; Eoin F McKinney; Mark R Wills; Ravindra K Gupta; John R Bradley; Rachael J M Bashford-Rogers; Paul A Lyons; Kenneth G C Smith
Journal:  Cell Rep       Date:  2022-01-31       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.